Multimodality imaging to assess immediate response to irreversible electroporation in a rat liver tumor model

Radiology

Volumn 271, Issue 3, 2014, Pages 721-729

  Zhang, Yue ^a,b   White, Sarah B ^b,d   Nicolai, Jodi R ^b   Zhang, Zhuoli ^b   West, Derek L ^b   Kim, Dong Hyun ^b   Lee Goodwin, A ^b   Miller, Frank H ^b   Omary, Reed A ^b   Larson, Andrew C ^a,b,c,e  

^a University of Illinois at Chicago   (United States)

^b Department of Radiology ^*  (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d MEDICAL COLLEGE OF WISCONSIN   (United States)

^e Northwestern University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABLATION THERAPY; ACCURACY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; ECHOGRAPHY; HEPATIC ARTERY LIGATION; HISTOPATHOLOGY; IMAGE ANALYSIS; INTERMETHOD COMPARISON; IRREVERSIBLE ELECTROPORATION ABLATION; LIVER TUMOR; MALE; MULTIMODAL IMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PREDICTION; PRIORITY JOURNAL; RAT; SIGNAL NOISE RATIO; TISSUE CHARACTERIZATION; TRANSMISSION ELECTRON MICROSCOPY;

ANIMALS; CONTRAST MEDIA; DISEASE MODELS, ANIMAL; ELECTROPORATION; LIVER NEOPLASMS, EXPERIMENTAL; MAGNETIC RESONANCE IMAGING; MALE; MICROSCOPY, ELECTRON; MICROSCOPY, FLUORESCENCE; MULTIMODAL IMAGING; RATS; RATS, SPRAGUE-DAWLEY; TOMOGRAPHY, X-RAY COMPUTED; ULTRASONOGRAPHY;

EID: 84901676315     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.14130989     Document Type: Article

References (43)

1. Rubinsky B, Onik G, Mikus P. Irreversible electroporation: a new ablation modality-clinical implications. Technol Cancer Res Treat 2007;6(1):37-48.
2. Lee E W, Loh CT, Kee ST. Imaging guided percutaneous irreversible electropora-tion: ultrasound and immunohistologi-cal correlation. Technol Cancer Res Treat 2007;6(4):287-294.
3. Edd JF, Horowitz L, Davalos RV, Mir LM, Rubinsky B. In vivo results of a new focal tissue ablation technique: irreversible electroporation. IEEE Trans Biomed Eng 2006;53(7):1409-1415.
4. Ahmed M, Goldberg SN. Thermal ablation therapy for hepatocellular carcinoma. J Vasc Interv Radiol 2002;13(9 Pt 2):S231-S244.
5. Boaz TL, Lewin JS, Chung YC, Duerk JL, Clampitt ME, Haaga JR. MR monitoring of MR-guided radiofrequency thermal ablation of normal liver in an animal model. J Magn Reson Imaging 1998;8(1):64-69.
6. Kingham TP, Karkar AM, D'Angelica MI, et al. Ablation of perivascular hepatic malignant tumors with irreversible elec-troporation. J Am Coll Surg 2012;215(3): 379-387.
7. Lee YJ, Lu DS, Osuagwu F, Lassman C. Irreversible electroporation in porcine liver: short-and long-term effect on the hepatic veins and adjacent tissue by CT with pathological correlation. Invest Radiol 2012;47(11):671-675.
8. Maor E, Ivorra A, Leor J, Rubinsky B. The effect of irreversible electroporation on blood vessels. Technol Cancer Res Treat 2007;6(4):307-312.
9. Guo Y, Zhang Y, Klein R, et al. Irreversible electroporation therapy in the liver: longitudinal effcacy studies in a rat model of hepatocellular carcinoma. Cancer Res 2010;70(4):1555-1563.
10. Lee EW, Wong D, Tafti BA, et al. Irreversible electroporation in eradication of rabbit VX2 liver tumor. J Vasc Interv Radiol 2012;23(6):833-840.
11. Sugiura N, Takara K, Ohto M, Okuda K, Hirooka N. Percutaneous intratumoral injection of ethanol under ultrasound imaging for treatment of small hepatocellular carcinoma. Acta Hepatol Jpn 1983;24:920-923.
12. Deng J, Virmani S, Yang GY, et al. Intra-procedural diffusion-weighted PROPELLER MRI to guide percutaneous biopsy needle placement within rabbit VX2 liver tumors. J Magn Reson Imaging 2009;30(2):366-373.
13. Brandt KR, Charboneau JW, Stephens DH, Welch TJ, Goellner JR. CT-and US-guided biopsy of the pancreas. Radiology 1993;187(1):99-104.
14. Gilbert JC, Onik GM, Hoddick WK, Rubinsky B. Real time ultrasonic monitoring of hepatic cryosurgery. Cryobiology 1985;22(4):319-330.
15. Nour SG, Goldberg SN, Wacker FK, et al. MR monitoring of NaCl-enhanced radiofrequency ablations: observations on low-and high-feld-strength MR images with pathologic correlation. Radiology 2010;254(2):449-459.
16. Holbrook AB, Santos JM, Kaye E, Rieke V, Pauly KB. Real-time MR thermometry for monitoring HIFU ablations of the liver. Magn Reson Med 2010;63(2):365-373.
17. Mikami S, Tateishi R, Akahane M, et al. Computed tomography follow-up for the detection of hepatocellular carcinoma recurrence after initial radiofrequency ablation: a single-center experience. J Vasc Interv Radiol 2012;23(10):1269-1275.
18. Krause BJ, Herrmann K, Wieder H, zum Büschenfelde CM. 18F-FDG PET and 18F-FDG PET/CT for assessing response to therapy in esophageal cancer. J Nucl Med 2009;50(Suppl 1):89S-96S.
19. Okuma T, Matsuoka T, Okamura T, et al. 18F-FDG small-animal PET for monitoring the therapeutic effect of CT-guided radio-frequency ablation on implanted VX2 lung tumors in rabbits. J Nucl Med 2006;47(8): 1351-1358.
20. Solbiati L, Giangrande A, De Pra L, Bellotti E, Cantù P, Ravetto C. Percutaneous etha-nol injection of parathyroid tumors under US guidance: treatment for secondary hy-perparathyroidism. Radiology 1985;155(3): 607-610.
21. Minami Y, Kudo M. Review of dynamic contrast-enhanced ultrasound guidance in ablation therapy for hepatocellular carcinoma. World J Gastroenterol 2011;17(45):4952-4959.
22. Solbiati L, Ierace T, Goldberg SN, et al. Percutaneous US-guided radio-frequency tissue ablation of liver metastases: treatment and follow-up in 16 patients. Radiology 1997;202(1):195-203.
23. Lee EW, Chen C, Prieto VE, Dry SM, Loh CT, Kee ST. Advanced hepatic ablation technique for creating complete cell death: irreversible electroporation. Radiology 2010;255(2): 426-433.
24. Thomson KR, Cheung W, Ellis SJ, et al. Investigation of the safety of irreversible elec-troporation in humans. J Vasc Interv Radiol 2011;22(5):611-621.
25. Zhang Y, Guo Y, Ragin AB, et al. MR imaging to assess immediate response to irreversible electroporation for targeted ablation of liver tissues: preclinical feasibility studies in a rodent model. Radiology 2010;256(2): 424-432.
26. Guo Y, Zhang Y, Nijm GM, et al. Irreversible electroporation in the liver: contrast-enhanced inversion-recovery MR imaging approaches to differentiate reversibly elec-troporated penumbra from irreversibly electroporated ablation zones. Radiology 2011;258(2):461-468.
27. Ellis TL, Garcia PA, Rossmeisl JH Jr, Henao-Guerrero N, Robertson J, Davalos RV. Non-thermal irreversible electroporation for in-tracranial surgical applications: laboratory investigation. J Neurosurg 2011;114(3): 681-688.
28. Appelbaum L, Ben-David E, Sosna J, Nis-senbaum Y, Goldberg SN. US fndings after irreversible electroporation ablation: radiologic-pathologic correlation. Radiology 2012;262(1):117-125.
29. Au JT, Kingham TP, Jun K, et al. Irreversible electroporation ablation of the liver can be detected with ultrasound B-mode and elastography. Surgery 2013;153(6): 787-793.
30. Collins JM, Despa F, Lee RC. Structural and functional recovery of electropermeabilized skeletal muscle in-vivo after treatment with surfactant poloxamer 188. Biochim Biophys Acta 2007;1768(5):1238-1246.
31. Park Y, Choi D, Rhim H, et al. Central lower attenuating lesion in the ablation zone on immediate follow-up CT after percutaneous radiofrequency ablation for he-patocellular carcinoma: incidence and clinical signifcance. Eur J Radiol 2010;75(3): 391-396.
32. Rossi S, Di Stasi M, Buscarini E, et al. Percutaneous RF interstitial thermal ablation in the treatment of hepatic cancer. AJR Am J Roentgenol 1996;167(3):759-768.
33. Lewin JS, Connell CF, Duerk JL, et al. Interactive MRI-guided radiofrequency interstitial thermal ablation of abdominal tumors: clinical trial for evaluation of safety and feasibility. J Magn Reson Imaging 1998;8(1): 40-47.
34. Clasen S, Pereira PL. Magnetic resonance guidance for radiofrequency ablation of liver tumors. J Magn Reson Imaging 2008;27(2):421-433.
35. Orlacchio A, Bazzocchi G, Pastorelli D, et al. Percutaneous cryoablation of small hepa-tocellular carcinoma with US guidance and CT monitoring: initial experience. Cardio-vasc Intervent Radiol 2008;31(3):587-594.
36. Lee SM, Won JY, Lee DY, et al. Percutaneous cryoablation of small hepatocellular carcinomas using a 17-gauge ultrathin probe. Clin Radiol 2011;66(8):752-759.
37. Silverman SG, Tuncali K, Adams DF, et al. MR imaging-guided percutaneous cryother-apy of liver tumors: initial experience. Radiology 2000;217(3):657-664.
38. Sofocleous CT, Klein KM, Hubbi B, et al. Histopathologic evaluation of tissue extracted on the radiofrequency probe after ablation of liver tumors: preliminary fndings. AJR Am J Roentgenol 2004;183(1):209-213.
39. Sofocleous CT, Nascimento RG, Petrovic LM, et al. Histopathologic and immuno-histochemical features of tissue adherent to multitined electrodes after RF ablation of liver malignancies can help predict local tumor progression: initial results. Radiology 2008;249(1):364-374.
40. Snoeren N, Huiskens J, Rijken AM, et al. Viable tumor tissue adherent to needle applicators after local ablation: a risk factor for local tumor progression. Ann Surg Oncol 2011;18(13):3702-3710.
41. Sofocleous CT, Garg S, Petrovic LM, et al. Ki-67 is a prognostic biomarker of survival after radiofrequency ablation of liver malignancies. Ann Surg Oncol 2012;19(13): 4262-4269.
42. Snoeren N, Jansen MC, Rijken AM, et al. Assessment of viable tumour tissue attached to needle applicators after local ablation of liver tumours. Dig Surg 2009;26(1):56-62.
43. Guo Y, Zhang Y, Jin N, et al. Electropora-tion-mediated transcatheter arterial chemo-embolization in the rabbit VX2 liver tumor model. Invest Radiol 2012;47(2):116-120.